Key result
Factor Xa and XIa inhibitors developed via molecular docking offer promising strategies against pathological thrombosis.
Why the study?
Disorders in the blood coagulation system are the leading cause of death and disability, making the search for drugs that prevent pathological thrombosis without affecting normal hemostasis increasingly relevant.
This review outlines the current understanding of blood coagulation and the potential of new Factor Xa and XIa inhibitors in preventing thrombosis.
Disorders in the blood coagulation system are the leading cause of death and disability in the modern world. So the search for new drugs that can prevent pathological thrombosis, while not affecting normal hemostasis, becomes more relevant than ever. Recent studies has been a revolution in the understanding of the principles of work and the regulation of blood coagulation. In addition, new, more effective approaches to drug development have now appeared. For example computer simulation methods that can significantly reduce the time and resources spent on the search for new candidate molecules. In the review, the blood clotting system, the molekular mechanisms of thrombosis, the role of blood coagulation factors Xa and XIa, and the urgency of developing new inhibitors of these targets are shown, and the most interesting inhibitors of factors Xa and XIa are presented.
No takes yet. Share an insight, caveat, or question.
Подоплелова et al. (2020) conducted a review in Blood coagulation disorders and thrombosis. Factor Xa and XIa inhibitors was evaluated. Factor Xa and XIa inhibitors, increasingly developed through computer simulation methods like molecular docking, offer promising new therapeutic strategies for preventing pathological thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: